In yesterday’s Wall Street session, Aclaris Therapeutics Inc (NASDAQ:ACRS) shares traded at $4.59, up 46.18% from the previous session.
ACRS stock price is now 187.31% away from the 50-day moving average and 251.72% away from the 200-day moving average. The market capitalization of the company currently stands at $327.86M.
With the price target enhanced from $2 to $7, Leerink Partners Upgraded its rating from Market Perform to Outperform for Aclaris Therapeutics Inc (NASDAQ: ACRS). On November 20, 2024, Jefferies Upgraded its previous ‘Hold’ rating to ‘Buy’ on the stock increasing its target price from $2 to quote $7, while ‘BTIG Research’ rates the stock as ‘Buy’
In other news, Leonard Braden Michael, 10% Owner bought 206,025 shares of the company’s stock on Aug 05 ’24. The stock was bought for $256,357 at an average price of $1.24. Upon completion of the transaction, the 10% Owner now directly owns 14,250,000 shares in the company, valued at $65.41 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 02 ’24, 10% Owner Leonard Braden Michael bought 167,544 shares of the business’s stock. A total of $216,400 was incurred on buying the stock at an average price of $1.29. This leaves the insider owning 14,043,975 shares of the company worth $64.46 million. A total of 4.01% of the company’s stock is owned by insiders.
During the past 12 months, Aclaris Therapeutics Inc has had a low of $0.77 and a high of $3.54. As of last week, the company has a debt-to-equity ratio of 0.02, a current ratio of 7.03, and a quick ratio of 7.03. The fifty day moving average price for ACRS is $1.5292 and a two-hundred day moving average price translates $1.2878 for the stock.
The latest earnings results from Aclaris Therapeutics Inc (NASDAQ: ACRS) was released for 2024-09-30. The net profit margin was -136.65% and return on equity was -25.83% for ACRS. The company reported revenue of $4.35 million for the quarter, compared to $9.28 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -53.18 percent.
